Zyprexa Relprevv

See also: Generic Zyprexa, Generic Zyprexa Zydis

Zyprexa Relprevv is a brand name of olanzapine, approved by the FDA in the following formulation(s):

ZYPREXA RELPREVV (olanzapine pamoate - suspension, extended release; intramuscular)

• 
  Manufacturer: ELI LILLY CO
  
  Approval date: December 11, 2009
  
  Strength(s): EQ 210MG BASE/VIAL, EQ 300MG BASE/VIAL, EQ 405MG BASE/VIAL ^[RLD]

Has a generic version of Zyprexa Relprevv been approved?

No. There is currently no therapeutically equivalent version of Zyprexa Relprevv available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyprexa Relprevv. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  2-methyl-thieno-benzodiazepine
  Patent 5,229,382
  Issued: July 20, 1993
  Inventor(s): Chakrabarti; Jiban K. & Hotten; Terrence M. & Tupper; David E.
  Assignee(s): Lilly Industries Limited
  2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
  
  Patent expiration dates:
  
  
  • October 23, 2011
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  2-methyl-thieno-benzodiazepine formulation
  Patent 6,169,084
  Issued: January 2, 2001
  Inventor(s): Bunnell; Charles Arthur & Ferguson; Thomas Harry & Hendriksen; Barry Arnold & Sanchez-Felix; Manuel Vicente & Tupper; David Edward
  Assignee(s): Eli Lilly and Company
  The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.
  
  Patent expiration dates:
  
  
  • September 30, 2018
    
    ✓ 
    Patent use: A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 11, 2012 - NEW PRODUCT
  
  

See also...

• Zyprexa Relprevv Consumer Information (Drugs.com)
• Zyprexa Relprevv Consumer Information (Wolters Kluwer)
• ZyPREXA Relprevv injection Consumer Information (Cerner Multum)
• Zyprexa Relprevv Advanced Consumer Information (Micromedex)
• Olanzapine Consumer Information (Wolters Kluwer)
• Olanzapine Extended-Release Consumer Information (Wolters Kluwer)
• Olanzapine Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Olanzapine Tablets Consumer Information (Wolters Kluwer)
• Olanzapine Consumer Information (Cerner Multum)
• Olanzapine injection Consumer Information (Cerner Multum)
• Olanzapine Advanced Consumer Information (Micromedex)
• Olanzapine Intramuscular Advanced Consumer Information (Micromedex)
• Olanzapine AHFS DI Monographs (ASHP)